Ives, A. N.; Sagendorf, T.; Nierves, L.; Lin, T.-T.; Dirice, E.; Kulkarni, R. N.; Pasa-Tolic, L.; Qian, W.-J.; Fulcher, J. M.

Type 1 diabetes (T1D) results from autoimmune-mediated destruction of insulin-producing {beta} cells in the pancreatic islet. This process is modulated by pro-inflammatory cytokine signaling, which have been previously shown to alter protein expression in ex vivo islets. Herein, we applied top-down proteomics to globally evaluate proteoforms from human islets treated with proinflammatory cytokines (interferon-{gamma} and interleukin-1{beta}). We measured 1636 unique proteoforms across 6 donors and two time points (control and 24-hours post-treatment) and observed consistent changes in abundance across the glicentin-related pancreatic polypeptide (GRPP) and major proglucagon fragment regions of glucagon, as well as the LF-19/catestatin and vasostatin-1/2 region of chromogranin-A. We also observe several proteoforms that increase after cytokine-treatment or are exclusively observed after cytokine-treatment including forms of beta-2 Microglobulin (B2M), high-mobility group N2 protein (HMGN2), and chemokine (C-X-C motif) ligands (CXCL). Together, our quantitative results provide a baseline proteoform profile for human islets and identify several proteoforms that may serve as interesting candidate markers for T1D progression or therapeutic intervention.